Immorta Bio's SenoVax Shows Strongest Senolytic Activity in Preclinical CTE Model

Key Insights

• Immorta Bio filed a U.S. patent application covering preclinical findings that senolytic approaches, including SenoVax immunotherapy, improved outcomes in experimental chronic traumatic encephalopathy (CTE) models.
• Among all senolytics tested, antibodies generated by SenoVax demonstrated the most pronounced effects in reducing CTE-associated signals in preclinical evaluations.
• The research reveals an unexpected connection between cellular senescence and CTE, suggesting that targeting senescent cells could represent a novel therapeutic approach for this progressive neurodegenerative condition.

Immorta Bio has announced preclinical findings demonstrating that its senolytic immunotherapy SenoVax showed superior activity compared to other senolytic approaches in experimental models of chronic traumatic encephalopathy (CTE). The Miami-based longevity company filed a U.S. patent application covering these unexpected results, which reveal a previously unknown connection between cellular senescence and CTE pathology.

Novel Senescence-CTE Connection Identified

The research identified cellular senescence as a potential driver of CTE-related inflammation and brain injury. "Our data suggest that cellular senescence is a driver of CTE-related inflammation and brain injury," said Thomas E. Ichim, PhD, President and Chief Scientific Officer of Immorta Bio. "In preclinical models, senolytic strategies reduced CTE-associated signals, with antibodies generated by SenoVax showing the most pronounced effects among the senolytics we evaluated."

CTE is a progressive neurodegenerative condition associated with repetitive head impacts in athletes, military veterans, and others. The disease is characterized by mood and behavior changes including depression and irritability, cognitive decline, and can progress to dementia. Currently, no approved disease-modifying treatments exist for CTE.

SenoVax Demonstrates Superior Efficacy

Among the various senolytic therapies tested in the study, SenoVax-induced antibodies exhibited the strongest effects in addressing CTE-associated pathology. The first-in-class senolytic immunotherapy works by training the immune system to clear senescent 'zombie' cells that are implicated in cancer immune evasion and aging processes.

SenoVax has previously demonstrated activity across multiple oncology models, showing tumor control in lung, breast, glioma, and pancreatic cancer settings. The therapy has also shown synergy with checkpoint inhibitors and immune rejuvenation signals through enhanced CD8 and NK cell activity.

Clinical Development Progress

Immorta Bio has filed an Investigational New Drug (IND) application to begin clinical evaluation of SenoVax in advanced non-small cell lung cancer (NSCLC). The company is currently working with the FDA on a defined GMP demonstration run, which represents the remaining step prior to IND clearance.

"Seeing our cancer immunotherapy show promise in a neurologic, trauma-linked disease underscores how longevity science can unlock cross-disciplinary therapies," said Boris N. Reznik, PhD, Chairman and CEO of Immorta Bio. "We're pressing forward to open our lung cancer trial and, in parallel, systematically explore CTE and other neurodegenerative indications."

Broader Therapeutic Implications

The findings suggest potential applications for senolytic immunotherapy beyond oncology, extending into neurodegenerative conditions linked to trauma. This cross-disciplinary approach reflects the company's mission of "Treating Diseases of Aging and Treating Aging as Disease."

Immorta Bio's research portfolio includes SenoVax and StemCellRevivify, a personalized cellular rejuvenation and exosome therapy. The company's focus on longevity science aims to develop personalized cellular and immune therapeutics targeting age-related diseases.